Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Plasma Cell Leukemia (PCL)

Tundra lists 3 Plasma Cell Leukemia (PCL) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07509086

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-04-03

1 state

Relapsed/Refractory Multiple Myeloma
Plasma Cell Leukemia (PCL)
NOT YET RECRUITING

NCT07185490

IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.

Gender: All

Ages: 18 Years - Any

Updated: 2026-01-20

Relapsed/Refractory Multiple Myeloma (RRMM)
Plasma Cell Leukemia (PCL)
RECRUITING

NCT07085559

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.

Gender: All

Ages: 19 Years - 75 Years

Updated: 2025-07-25

1 state

Multiple Myeloma (MM)
Plasma Cell Leukemia (PCL)
AL Amyloidosis (AL)